#France #N/A #Molecular Diagnostics #Seegene #CURECA

Seegene Establishes French Subsidiary to Expand European Market Presence

In a significant move to strengthen its foothold in Europe, Seegene, Inc.—a prominent name in molecular diagnostics—has announced the opening of its eighth international subsidiary in France. This expansion comes as the company seeks to accelerate sales and enhance customer engagement in one of Europe’s largest markets for molecular diagnostics.

A Growing Market for Molecular Diagnostics in France

France is recognized as the second-largest market for molecular diagnostics in Europe, trailing only Germany, which holds a 19% share of the regional market. According to Grand View Research, Inc., the French market is projected to reach approximately €600 million, accounting for about 15% of the total European market. This growth can largely be attributed to an increasing demand for diagnostic testing related to sexually transmitted infections (STIs), gastrointestinal infections, and respiratory viruses, positioning Seegene to capitalize on this trend.

Objectives of the New Subsidiary

The newly established French subsidiary aims to enhance local contact with customers and partners. Seegene plans to provide improved technical support and market development while collaborating with stakeholders in the healthcare sector. As Daniel Shin, Seegene's Executive Vice President and Chief Global Commercial and Marketing Officer, stated, the subsidiary will facilitate a deeper understanding of the French healthcare landscape and elevate local customer services.

This strategic move is vital as it also aims to expedite the adoption of Seegene’s cutting-edge diagnostic solutions such as CURECA™, a fully automated PCR system, and STAgora™, a platform designed for real-time analysis of diagnostic data and predictive insights.

Importance of Local Expertise

One of the primary advantages of establishing a subsidiary in France is the ability to deliver innovative products swiftly to meet the efficiency needs of local laboratories. “In the competitive French market, being able to quickly meet the demands of both the private and public health sectors is crucial for success,” Shin emphasized. The new branch will help Seegene better align its offerings with market requirements, thus fostering growth in the in-vitro diagnostic space.

International Expansion and Revenue Insights

With the establishment of its French subsidiary, Seegene's overseas business units now total eight, enriching its global distribution network, which includes 90 distributors across 94 countries. As of the first half of 2025, international sales constituted approximately 93% of Seegene’s total revenue, with Europe representing a notable 63% of that figure. This highlights Europe’s vital role as a growth engine in Seegene’s global expansion strategy.

The Future and Innovations

The launch of the French subsidiary is expected to accelerate the development and dissemination of Seegene's diagnostic products in Europe, particularly in innovative areas like cervical cancer screening and other multiplex diagnostic categories.

As Seegene continues to navigate a rapidly evolving market, its establishment in France is seen as a pivotal step towards reinforcing its European presence while further its commitment to advancing public health through high-quality diagnostic solutions.

For more information on Seegene's innovative approaches in molecular diagnostics, visit Seegene.com or follow them on LinkedIn.